G1 Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. Co.'s primary compound trilaciclib is a therapy designed to help protect against chemotherapy-induced myelosuppression. Trilaciclib helps protect hematopoietic stem and progenitor cells in the bone marrow by transiently inhibiting CDK4/6 leading to a temporary arrest of susceptible host cells during chemotherapy in patients. Rintodestrant is an oral selective estrogen receptor degrader for the treatment of ER+ breast cancer. The GTHX stock yearly return is shown above.
The yearly return on the GTHX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GTHX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|